Rautanen Tomi, Ahopelto Kaisa, Niinikoski Harri, Karppinen Sinikka, Lempinen Marko, Ortiz Fernanda, Helanterä Ilkka
Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Department of Pediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
Clin Kidney J. 2024 Nov 22;18(1):sfae373. doi: 10.1093/ckj/sfae373. eCollection 2025 Jan.
Lysinuric protein intolerance (LPI) is a metabolic disorder that leads to dysfunctional intestinal absorption and kidney clearance of cationic amino acids. Chronic kidney disease develops in many LPI patients and leads to end-stage kidney disease in at least 10% of patients. Since data on kidney transplants in LPI patients are limited, we analysed the outcomes of LPI patients after transplantation in Finland.
This retrospective cohort study includes all Finnish LPI patients who have received a kidney transplant. The data were collected from the Finnish Transplant Registry and electronic medical records from 2005 through May 2023 or patient death. The plasma amino acid profile was analysed before and after transplantation.
Eight LPI patients (75% female, mean age at transplant 41.9 years) received a kidney allograft and two of the patients received a second transplant. Nine transplants were from deceased donors and one was from a living donor. Acute rejection occurred after four transplantations (two T-cell mediated and two antibody mediated). One patient died 6 months after transplantation due to alveolar proteinosis. Apart from lower citrulline and higher lysine concentrations, plasma amino acid levels showed no changes after transplantation. The 1-, 5- and 10-year graft survivals were 80%, 68.6% and 51.4%, and patient survivals were 88%, 86% and 50%, respectively.
Kidney transplantation is feasible in patients with LPI, although the acute rejection rate seems high and severe complications such as pulmonary alveolar proteinosis may occur. Transplantation led to changes in plasma citrulline and lysine concentrations.
赖氨酸尿性蛋白不耐受症(LPI)是一种代谢紊乱疾病,可导致阳离子氨基酸的肠道吸收功能障碍和肾脏清除功能异常。许多LPI患者会发展为慢性肾脏病,至少10%的患者会发展为终末期肾病。由于LPI患者肾移植的数据有限,我们分析了芬兰LPI患者移植后的结局。
这项回顾性队列研究纳入了所有接受肾移植的芬兰LPI患者。数据收集自芬兰移植登记处以及2005年至2023年5月的电子病历,直至患者死亡。分析移植前后的血浆氨基酸谱。
8例LPI患者(75%为女性,移植时平均年龄41.9岁)接受了同种异体肾移植,其中2例患者接受了第二次移植。9例移植来自 deceased 供体,1例来自活体供体。4次移植后发生了急性排斥反应(2次由T细胞介导,2次由抗体介导)。1例患者在移植后6个月因肺泡蛋白沉积症死亡。除瓜氨酸浓度降低和赖氨酸浓度升高外,移植后血浆氨基酸水平无变化。1年、5年和10年的移植物存活率分别为80%、68.6%和51.4%,患者存活率分别为88%、86%和50%。
LPI患者可行肾移植,尽管急性排斥反应率似乎较高,且可能发生肺泡蛋白沉积症等严重并发症。移植导致血浆瓜氨酸和赖氨酸浓度发生变化。